Talphera CEO Vince Angotti confirmed that the company has finished realigning its clinical sites, ensuring all target locations are now active. This operational milestone aligns with a favorable shift in the regulatory landscape, as the 2026 KDIGO guidelines now recognize nafamostat as an acceptable anticoagulant for continuous renal replacement therapy. This update represents a distinct change from prior clinical recommendations and strengthens the potential commercial path for the company’s lead candidate, Niyad.
Talphera Advances Nafamostat Study Amid Rising CRRT Market Projections
With enrollment for its NEPHRO CRRT clinical trial reaching 75 percent, Talphera is moving toward a year-end conclusion for its nafamostat development program. The company reports that updated market research now projects 200,000 annual U.S. procedures for the therapy, marking a significant 21 percent increase over previous estimates.
Financially, the company reported a cash and investment balance of $17.1 million as of June 30, 2026. The net loss for the second quarter reached $4.3 million, compared to $3.5 million during the same period last year, a variance primarily driven by higher development expenses associated with the ongoing trial. Talphera recently regained compliance with Nasdaq’s $1 minimum bid price rule and plans to host an investor event to discuss future commercial opportunities as trial enrollment nears its final phase.
Comments (0)
No comments yet. Be the first!